Grifols launches FESILTY in the US: a new treatment for fibrinogen deficiency -

Grifols Photography.

Expansion in the US market

Spanish pharmaceutical company Grifols has announced the launch in the United States of FESILTY™, a new fibrinogen concentrate. Approved by the FDA, this treatment is intended for acute bleeding episodes in patients with Congenital Fibrinogen Deficiency (CFD), strengthening the company's presence in the North American market.

The global healthcare company Grifols has begun marketing in United States of their new fibrinogen concentrate, FESILTY™This strategic launch comes after receiving approval from Administración de Alimentos y Medicamentos de EE. UU. (FDA), and is aimed at the treatment of acute bleeding episodes in pediatric and adult patients suffering from congenital fibrinogen deficiency (CFD), a rare inherited condition.

This move not only expands the Spanish multinational's portfolio of bleeding treatments but also offers a crucial new therapeutic option for a condition where speed and effectiveness are vital. Fibrinogen deficiency (FDD), which includes hypo- or afibrinogenemia, impairs the proper production or function of fibrinogen, a plasma protein essential for clotting and wound healing. Without adequate levels of this protein, the body cannot effectively stop bleeding.

An innovative solution to traditional treatments

FESILTY™ is presented as a highly purified product with a precise amount of fibrinogen, allowing healthcare professionals to quickly and, above all, predictably replenish levels of this protein. This feature is especially relevant in critical bleeding situations, where every minute counts. The new treatment of Grifols It offers significant advantages over existing therapeutic alternatives, such as cryoprecipitate and frozen plasma.

These traditional alternatives contain additional non-essential proteins, often require the administration of large volumes to be effective, and are slower to prepare. In contrast, FESILTY™ can be stored at room temperature and its supply kit makes it easy Rapid reconstitution in approximately three minutes, optimizing response times in medical emergencies.

Feature	Description
Product	FESILTY™
Company	Grifols
Launch Market	United States
Therapeutic Indication	Acute bleeding episodes in patients with Congenital Fibrinogen Deficiency (CFD)
Regulatory Approval	Administración de Alimentos y Medicamentos de EE. UU. (FDA)
Key Advantage	Rapid reconstitution (approx. 3 minutes) and predictable dosage.

Clinical support and strategic vision

The approval of the FDA It is based on the results of a robust phase I/III clinical trial that confirmed the pharmacokinetics, hemostatic efficacy, and safety of the treatment in both adults and children. The findings of this research have recently been published in prestigious medical journals. 'Thrombosis and Haemostasis' (October 2025) and 'Thrombosis Research' (March 2026).

Industry experts, such as Dr. Guy Young, Director of Centro de Hemostasia y Trombosis from the Escuela de Medicina Keck from the Universidad del Sur de CaliforniaThey have positively assessed the arrival of this new concentrate. "The availability of an additional fibrinogen concentrate in EE. UU. "This represents a significant advance," Dr. [Name] notes. Young"Targeted fibrinogen replacement is gaining increasing support, and purified concentrates can be particularly useful as they allow for predictable dosing, can be administered quickly, and do not require cross-compatibility testing."

For its part, Roland Wandeler, President of Grifols BiopharmaThis underscores the company's commitment to patients. "Now that FESILTY™ is available in EE. UU.“Healthcare professionals now have a safe, effective, and reliable treatment for acute bleeding episodes in patients with CF, when every minute counts,” he says. “This milestone reflects our ongoing commitment to bringing more medicines to more patients around the world.”

Key points and frequently asked questions about the launch of FESILTY™ by Grifols in the USA.

What are the implications of this launch for a Spanish company like Grifols?

To Grifols, the launch of FESILTYThe acquisition of this product in the United States represents a key consolidation in the world's largest pharmaceutical market. It reinforces its leading position in plasma-derived medicines, diversifies its revenue streams in a strategic market, and demonstrates its capacity for innovation and overcoming demanding regulatory barriers. FDA, a globally recognized seal of quality.

How does FESILTY™ affect competition in the blood products sector?

The introduction of FESILTY™ increases competition by offering a high-purity, rapid-administration alternative to more traditional treatments. Its advantages in predictable dosing and ease of use can position it as a preferred option in emergency situations, forcing other market players to innovate or compete on efficiency and cost.

What should healthcare managers know about FDA approval for these types of products?

The approval of the FDA It is a rigorous and costly process that validates a product's safety and efficacy internationally. For Spanish biopharmaceutical executives and exporters, a milestone like this underscores the importance of investing in R&D and robust clinical trials to access high-value markets. Furthermore, approval from the FDA It can facilitate entry into other regulatory markets that use it as a benchmark.